The use of human insulin derived from baker's yeast by recombinant DNA technology

Philip Raskin, R. S. Clements

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Human insulin has gradually replaced animal insulin as the therapeutic agent of first choice among insulin-dependent and insulin-requiring patients with diabetes. Like animal insulin, human insulin manufactured by several different methods is available in Regular, NPH, Lente ®, and 70/30 (NPH/Regular) formulations. The most recently developed method of manufacturing human insulin uses recombinant DNA technology with baker's yeast as the host cell [rDNA HI (BY)], offering potentially limitless supplies of insulin structurally identical to that made by the human pancreas. Clinical studies have demonstrated that the extent of insulin absorption, the glucose-lowering effects, and the clinical effects on glycemic control and on incidence of hypoglycemia with rDNA HI (BY) are similar to those observed when patients are treated with semisynthetic human insulin (ssHI). Dose-for-dose transfer of patients from ssHI to rDNA HI (BY) is therefore appropriate. It is standard practice to recommend that any change in insulin be conducted under medical supervision.

Original languageEnglish (US)
Pages (from-to)569-578
Number of pages10
JournalClinical Therapeutics
Volume13
Issue number5
StatePublished - 1991

Fingerprint

Recombinant DNA
Saccharomyces cerevisiae
Insulin
Technology
Ribosomal DNA
Patient Transfer
Hypoglycemia
Pancreas

ASJC Scopus subject areas

  • Pharmacology

Cite this

The use of human insulin derived from baker's yeast by recombinant DNA technology. / Raskin, Philip; Clements, R. S.

In: Clinical Therapeutics, Vol. 13, No. 5, 1991, p. 569-578.

Research output: Contribution to journalArticle

@article{f894e4da32cd460e9597235435199d7a,
title = "The use of human insulin derived from baker's yeast by recombinant DNA technology",
abstract = "Human insulin has gradually replaced animal insulin as the therapeutic agent of first choice among insulin-dependent and insulin-requiring patients with diabetes. Like animal insulin, human insulin manufactured by several different methods is available in Regular, NPH, Lente {\circledR}, and 70/30 (NPH/Regular) formulations. The most recently developed method of manufacturing human insulin uses recombinant DNA technology with baker's yeast as the host cell [rDNA HI (BY)], offering potentially limitless supplies of insulin structurally identical to that made by the human pancreas. Clinical studies have demonstrated that the extent of insulin absorption, the glucose-lowering effects, and the clinical effects on glycemic control and on incidence of hypoglycemia with rDNA HI (BY) are similar to those observed when patients are treated with semisynthetic human insulin (ssHI). Dose-for-dose transfer of patients from ssHI to rDNA HI (BY) is therefore appropriate. It is standard practice to recommend that any change in insulin be conducted under medical supervision.",
author = "Philip Raskin and Clements, {R. S.}",
year = "1991",
language = "English (US)",
volume = "13",
pages = "569--578",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "5",

}

TY - JOUR

T1 - The use of human insulin derived from baker's yeast by recombinant DNA technology

AU - Raskin, Philip

AU - Clements, R. S.

PY - 1991

Y1 - 1991

N2 - Human insulin has gradually replaced animal insulin as the therapeutic agent of first choice among insulin-dependent and insulin-requiring patients with diabetes. Like animal insulin, human insulin manufactured by several different methods is available in Regular, NPH, Lente ®, and 70/30 (NPH/Regular) formulations. The most recently developed method of manufacturing human insulin uses recombinant DNA technology with baker's yeast as the host cell [rDNA HI (BY)], offering potentially limitless supplies of insulin structurally identical to that made by the human pancreas. Clinical studies have demonstrated that the extent of insulin absorption, the glucose-lowering effects, and the clinical effects on glycemic control and on incidence of hypoglycemia with rDNA HI (BY) are similar to those observed when patients are treated with semisynthetic human insulin (ssHI). Dose-for-dose transfer of patients from ssHI to rDNA HI (BY) is therefore appropriate. It is standard practice to recommend that any change in insulin be conducted under medical supervision.

AB - Human insulin has gradually replaced animal insulin as the therapeutic agent of first choice among insulin-dependent and insulin-requiring patients with diabetes. Like animal insulin, human insulin manufactured by several different methods is available in Regular, NPH, Lente ®, and 70/30 (NPH/Regular) formulations. The most recently developed method of manufacturing human insulin uses recombinant DNA technology with baker's yeast as the host cell [rDNA HI (BY)], offering potentially limitless supplies of insulin structurally identical to that made by the human pancreas. Clinical studies have demonstrated that the extent of insulin absorption, the glucose-lowering effects, and the clinical effects on glycemic control and on incidence of hypoglycemia with rDNA HI (BY) are similar to those observed when patients are treated with semisynthetic human insulin (ssHI). Dose-for-dose transfer of patients from ssHI to rDNA HI (BY) is therefore appropriate. It is standard practice to recommend that any change in insulin be conducted under medical supervision.

UR - http://www.scopus.com/inward/record.url?scp=0025720014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025720014&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 569

EP - 578

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 5

ER -